To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma ( DLBCL ) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab , doxorubicin , cyclophosphamide , vindesine , bleomycin , and prednisone ( R-ACVBP ) compared with standard rituximab , doxorubicin , cyclophosphamide , vincristine , and prednisone ( R-CHOP ) .